Salidroside inhibits renal ischemia/reperfusion injury‑induced ferroptosis by the PI3K/AKT signaling pathway

• DOI: 10.3892/etm.2023.12206
• Publication Date: 2023-09-14T14:58:49Z
• Authors: Zhe Tang; Yong Wang; Yan Liu; Chenglong Li
• Keywords: Viability assay

Renal ischemia/reperfusion injury (RIRI) represents the principal factor underlying acute kidney (AKI), which primarily stems from cellular injuries and ferroptosis caused by reactive oxygen species (ROS). Salidroside (SA), an antioxidant natural ester, has been attributed with potential to protect against RIRI. In present study, rats received daily SA doses (1, 10, or 100 mg/kg) gavage for 7 consecutive days before surgery. The results revealed aggravated renal in RIRI group, was effectively prevented pretreatment (10 mg/kg), 1 mg/kg dosage demonstrating lesser efficacy. Additionally, indicated that mitigated RIRI-related upregulation of antioxidative superoxide dismutase. vitro studies corroborated SA's ability maintain hypoxia/reoxygenation-treated NRK cell viability, protective effect being observed at concentrations ≥1 µM peaking µM. Furthermore, showed safeguarded tubular epithelial cells oxidative damage, reduced ROS accumulation, inhibited via activation PI3K/AKT signaling pathway. Therefore, study highlight promising therapeutic as effective intervention targeting pathway-mediated anti-oxidative anti-ferroptotic mechanisms.